2018 / 02

Next Paper
DOI: 10.24075/brsmu.2018.026

ORIGINAL RESEARCH

Human enteroviruses exhibit selective oncolytic activity in the model of human glioblastoma multiforme xenografts in immunodeficient mice

Zheltukhin AO1, Soboleva AV1,2, Sosnovtseva AO1,3, Le TH1, Ilyinskaya GV1,4, Kochetkov DV1, Lipatova AV1, Chumakov PM1,2
About authors

1 Engelhardt Institute of Molecular Biology, Moscow, Russia

2 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow

3 Pirogov Russian National Research Medical University, Moscow, Russia

4 N. N. Blokhin Russian Cancer Research Center, Moscow, Russia

Correspondence should be addressed: Peter M. Chumakov
ul. Vavilova, 32, Moscow, 119991; moc.oohay@mpvokamuhc

About paper

Funding: the study was supported by the Ministry of Education and Science of the Russian Federation; project code RFMEFI60714X0014.

Received: 2018-06-26 Accepted: 2018-06-30 Published online: 2018-07-13
|
  1. Gubanova NV, Gaytan АS, Razumov IA, Mordvinov VA, Krivoshapkin АL, Netesov SV, i dr. Onkoliticheskie virusy v terapii gliom. Molekuljarnaja biologija. 2012; 46 (6): 726–38.
  2. Greenberg MS. Handbook of Neurosurgery. 7th ed. New York: Thieme Publishers; 2010.
  3. Park DM, Rich JN. Biology of glioma cancer stem cells. Molecules and cells. 2009; 28 (1): 7–12. DOI: 10.1007/s10059-009-0111-2. PubMed PMID: 19655094.
  4. Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol. 2007; 114 (5): 443–58. DOI: 10.1007/ s00401-007-0293-7. PubMed PMID: 17805551; PubMed Central PMCID: PMCPMC2039798.
  5. Buonaguro FM, Tornesello ML, Izzo F, Buonaguro L. Oncolytic virus therapies. Pharmaceutical patent analyst. 2012; 1 (5): 621– 27. DOI: 10.4155/ppa.12.65. PubMed PMID: 24236929.
  6. Parker JN, Bauer DF, Cody JJ, Markert JM. Oncolytic viral therapy of malignant glioma. Neurotherapeutics. 2009; 6 (3): 558–69.
  7. Zulkifli MM, Ibrahim R, Ali AM, Aini I, Jaafar H, Hilda SS, et al. Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma. Neurological research. 2009; 31 (1): 3–10. DOI: 10.1179/174313208x325218. PubMed PMID: 18937888.
  8. Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O, et al. Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. Apmis. 2006; 114 (10): 731–43.
  9. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2006; 13 (1): 221–28.
  10. Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B, et al. MTH-68/H oncolytic viral treatment in human high- grade gliomas. J Neurooncol. 2004; 67 (1–2): 83–93.
  11. Csatary LK, Bakacs T. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA. 1999; 281 (17): 588–89.
  12. Tsamis KI, Alexiou GA, Vartholomatos E, Kyritsis AP. Combination treatment for glioblastoma cells with tumor necrosis factor-related apoptosis-inducing ligand and oncolytic adenovirus delta-24. Cancer Invest. 2013; 31 (9): 630–38. DOI: 10.3109/07357907.2013.849724. PubMed PMID: 24164301.
  13. Li X, Mao Q, Wang D, Xia H. A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy. Int J Oncol. 2012; 41 (6): 2159–65. DOI: 10.3892/ijo.2012.1674. PubMed PMID: 23117867.
  14. Alonso MM, Jiang H, Gomez-Manzano C, Fueyo J. Targeting brain tumor stem cells with oncolytic adenoviruses. Methods Mol Biol. 2012; 797: 111–25.
  15. Ahmed AU, Ulasov IV, Mercer RW, Lesniak MS. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol Biol. 2012; 797: 97–109.
  16. Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses for the treatment of brain tumors. Curr Opin Mol Ther. 2010; 12 (5): 530– 37.
  17. Lacroix J, Schlund F, Leuchs B, Adolph K, Sturm D, Bender S, et al. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. Int J Cancer. 2014; 134 (3): 703–16. DOI: 10.1002/ ijc.28386. PubMed PMID: 23852775.
  18. Paglino JC, Ozduman K, van den Pol AN. LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells. J Virol. 2012; 86 (13): 7280–91.
  19. Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M, et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC cancer. 2012; 12: 99.
  20. Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther. 2014; 22 (5): 1056–62. DOI: 10.1038/mt.2014.21. PubMed PMID: 24553100; PubMed Central PMCID: PMCPMC4015229.
  21. van den Wollenberg DJ, Dautzenberg IJ, van den Hengel SK, Cramer SJ, de Groot RJ, Hoeben RC. Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A. PLoS One. 2012; 7 (10): e48064. DOI: 10.1371/journal.pone.0048064. PubMed PMID: 23110175; PubMed Central PMCID: PMCPMC3480499.
  22. Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther. 2008; 16 (3): 627–32.
  23. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst. 2001; 93 (12): 903–12. PubMed PMID: 11416111.
  24. Goetz C, Dobrikova E, Shveygert M, Dobrikov M, Gromeier M. Oncolytic poliovirus against malignant glioma. Future Virol. 2011; 6 (9): 1045–58.
  25. Goetz C, Gromeier M. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev. 2010; 21 (2–3): 197–203. DOI: 10.1016/j.cytogfr.2010.02.005. PubMed PMID: 20299272; PubMed Central PMCID: PMCPMC2881183.
  26. Dobrikova EY, Broadt T, Poiley-Nelson J, Yang X, Soman G, Giardina S, et al. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol Ther. 2008; 16 (11): 1865–72.
  27. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA. 2000; 97 (12): 6803–08.
  28. Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic Viruses in Cancer Treatment: A Review. JAMA oncology. 2017; 3 (6): 841–49. DOI: 10.1001/jamaoncol.2016.2064. PubMed PMID: 27441411.
  29. Pol J, Buque A, Aranda F, Bloy N, Cremer I, Eggermont A, et al. Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology. 2016; 5 (2): e1117740. DOI: 10.1080/2162402x.2015.1117740. PubMed PMID: 27057469; PubMed Central PMCID: PMCPMC4801444.
  30. Taguchi S, Fukuhara H, Homma Y, Todo T. Current status of clinical trials assessing oncolytic virus therapy for urological cancers. Int J Urol. 2017; 24 (5): 342–51. DOI: 10.1111/iju.13325. PubMed PMID: 28326624.
  31. Warner SG, O'Leary MP, Fong Y. Therapeutic oncolytic viruses: clinical advances and future directions. Curr Opin Oncol. 2017; 29 (5): 359–65. DOI: 10.1097/cco.0000000000000388. PubMed PMID: 28678032.
  32. Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, et al. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res. 2013; 73 (2): 865–74. DOI: 10.1158/0008-5472.can-12-2221. PubMed PMID: 23293278.
  33. Berghauser Pont LM, Balvers RK, Kloezeman JJ, Nowicki MO, van den Bossche W, Kremer A, et al. In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells. Gene Ther. 2015. DOI: 10.1038/ gt.2015.72. PubMed PMID: 26196249.
  34. Dey M, Ulasov IV, Lesniak MS. Virotherapy against malignant glioma stem cells. Cancer Lett. 2010; 289 (1): 1–10.
  35. Liu J, Ma L, Xu J, Liu C, Zhang J, Liu J, et al. Spheroid body- forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties. Int J Oncol. 2013; 42 (2): 453–59. DOI: 10.3892/ijo.2012.1720. PubMed PMID: 23229446; PubMed Central PMCID: PMCPMC3583623.
  36. Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem cells translational medicine. 2012; 1 (4): 322–32. DOI: 10.5966/sctm.2011-0035. PubMed PMID: 23197811; PubMed Central PMCID: PMCPMC3659700.
  37. van den Hengel SK, Balvers RK, Dautzenberg IJ, van den Wollenberg DJ, Kloezeman JJ, Lamfers ML, et al. Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures. Cancer Gene Ther. 2013; 20 (9): 507–13. DOI: 10.1038/ cgt.2013.47. PubMed PMID: 23907517.
  38. Chumakov PM, Morozova VV, Babkin IV, Baykov IK, Netesov SV, Tikunova NV. Onkoliticheskie enterovirusy. Molekuljarnaja biologija. 2012; 46 (6): 712–25.
  39. Voroshilova MK, Magazanik SS, Chumakov PM. Poleznye virusy cheloveka. Aktual’nye voprosy epidemiologii, mikrobiologii i infekzionnyh zabolevaniy. Tashkent: Medicina; 1980. p. 227–29.
  40. Wang X, Yang K, Xie Q, Wu Q, Mack SC, Shi Y, et al. Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. Nature neuroscience. 2017; 20 (5): 661–73. DOI: 10.1038/nn.4537. PubMed PMID: 28346452; PubMed Central PMCID: PMCPMC6015494.
  41. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015; 29 (12): 1203–17. DOI: 10.1101/gad.261982.115. PubMed PMID: 26109046; PubMed Central PMCID: PMCPMC4495393.
  42. Desjardins A, Gromeier M, Herndon JE, 2nd, Beaubier N, Bolognesi DP, Friedman AH, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med. 2018; DOI: 10.1056/ NEJMoa1716435. PubMed PMID: 29943666.